High diagnostic performance of plasma and cerebrospinal fluid beta-synuclein for sporadic Creutzfeldt-Jakob disease.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
25
07
2023
received:
23
06
2023
accepted:
28
07
2023
medline:
23
10
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
ppublish
Résumé
Beta-synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. Here we analysed its accuracy in the discrimination between sporadic Creutzfeldt-Jakob disease (n = 150) and non-prion rapidly progressive dementias (n = 106). In cerebrospinal fluid, beta-synuclein performed better than protein 14-3-3 (AUC 0.95 vs. 0.89) and, to a lesser extent, than total tau (AUC 0.92). Further, the diagnostic value of plasma beta-synuclein (AUC 0.91) outperformed that of plasma tau (AUC 0.79) and neurofilament light chain protein (AUC 0.65) and was comparable to that of cerebrospinal fluid biomarkers. Beta-synuclein might represent the first highly accurate blood biomarker for the diagnosis of sporadic Creutzfeldt-Jakob disease.
Identifiants
pubmed: 37553789
doi: 10.1002/acn3.51873
pmc: PMC10578883
doi:
Substances chimiques
beta-Synuclein
0
14-3-3 Proteins
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1904-1909Informations de copyright
© 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1181-1188
pubmed: 32928934
Alzheimers Dement. 2015 Dec;11(12):1461-1469
pubmed: 26092348
Ann Neurol. 1999 Aug;46(2):224-33
pubmed: 10443888
J Neurol Neurosurg Psychiatry. 2018 May;89(5):461-466
pubmed: 29142140
J Neurol Neurosurg Psychiatry. 2021 Apr;92(4):349-356
pubmed: 33380492
J Proteome Res. 2020 Mar 6;19(3):1310-1318
pubmed: 32101007
JAMA Neurol. 2019 Aug 01;76(8):969-977
pubmed: 31058916
J Neurol. 2019 Dec;266(12):3136-3143
pubmed: 31541342
Mol Psychiatry. 2021 Oct;26(10):5955-5966
pubmed: 33674752
J Neurol Neurosurg Psychiatry. 2022 Aug 22;:
pubmed: 35995553
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
J Neurol Neurosurg Psychiatry. 2017 Sep;88(9):764-772
pubmed: 28668775
Nat Rev Neurol. 2022 Jun;18(6):363-376
pubmed: 35508635
Neurology. 2022 Apr 5;98(14):e1434-e1445
pubmed: 35110380
JAMA Netw Open. 2022 Jan 4;5(1):e2146319
pubmed: 35099544
Int J Mol Sci. 2022 Feb 12;23(4):
pubmed: 35216166
Alzheimers Res Ther. 2021 Apr 21;13(1):86
pubmed: 33883011
Lancet Neurol. 2021 Mar;20(3):235-246
pubmed: 33609480
J Neurol Neurosurg Psychiatry. 2023 Feb;94(2):121-129
pubmed: 36428087
Sci Rep. 2017 Sep 6;7(1):10655
pubmed: 28878311